Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
AIMS: The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). METHODS AND RESULTS: ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P = 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P = 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P < 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldosterone relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P = 0.07 for interaction). CONCLUSION: This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Self-citationSolomon, S. D., Dobson, J., Pocock, S., Skali, H., McMurray, J. J. V., Granger, C. B., Yusuf, S., Swedberg, K., Young, J. B., Michelson, E. L., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.696906 · Cited by 681
Self-citationSarma, S., Mentz, R. J., Kwasny, M. J., Fought, A. J., Huffman, M., Subacius, H., Nodari, S., Konstam, M., Swedberg, K., Maggioni, A. P., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs153 · Cited by 202
Greenberg, B. H., Abraham, W. T., Albert, N. M., Chiswell, K., Clare, R., Stough, W. G., Gheorghiade, M., O'Connor, C. M., Sun, J. L., Yancy, C. W., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.05.001 · Cited by 196
Self-citation
Cited by
Type-2 diabetes mellitus and cardiovascular disease
Henning, R. J. (2018) · Future Cardiology · doi:10.2217/fca-2018-0045 · Cited by 398
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure
Dei Cas, A., Khan, S. S., Butler, J., Mentz, R. J., Bonow, R. O., Avogaro, A., Tschoepe, D., Doehner, W., Greene, S. J., Senni, M., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.004 · Cited by 401
Self-citationGreene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
“Likewise, among patients hospitalized for HF, the prevalence of DM may exceed 40% (11,12).”
BackgroundSelf-citation
Metadata
- Authors
- Maggioni, A. P., Greene, S. J., Fonarow, G. C., Bohm, M., Zannad, F., Solomon, S. D., Lewis, E. F., Baschiera, F., Hua, T. A., Gimpelewicz, C. R., Lesogor, A., Gheorghiade, M., for the ASTRONAUT Investigators and Coordinators, Ramos, S., Luna, A., Miriuka, S., Diez, M., Perna, E., Luquez, H., Pinna, J. G., Castagnino, J., Alvarenga, P., Ibanez, J., Blumberg, E. S., Dizeo, C., Guerrero, R. A., Schygiel, P., Milesi, R., Sosa, C., Hominal, M., Marquez, L. L., Poy, C., Hasbani, E., Vico, M., Fernandez, A., Vita, N., Vanhaecke, J., De Keulenaer, G., Striekwold, H., Vervoort, G., Vrolix, M., Henry, P., Dendale, P., Smolders, W., Marechal, P., Vandekerckhove, H., Oliveira, M., Neuenschwande, F., Reis, G., Saraiva, J., Bodanese, L., Canesin, M., Greco, O., Bassan, R., Marino, R. L., Giannetti, N., Moe, G., Sussex, B., Sheppard, R., Huynh, T., Stewart, R., Haddad, H., Echeverria, L., Quintero, A., Torres, A., Jaramillo, M., Lopez, M., Mendoza, F., Florez, N., Cotes, C., Garcia, M., Belohlavek, J., Hradec, J., Peterka, M., Gregor, P., Monhart, Z., Jansky, P., Kettner, J., Reichert, P., Spinar, J., Brabec, T., Hutyra, M., Solar, M., Pietila, M., Nyman, K., Pajari, R., Cohen, A., Galinier, M., Gosse, P., Livarek, B., Neuder, Y., Jourdain, P., Picard, F., Isnard, R., Hoppe, U., Kaeaeb, S., Rosocha, S., Prondzinsky, R., Felix, S., Duengen, H.-D., Figulla, H.-R., Fischer, S., Behrens, S., Stawowy, P., Kruells-Muench, J., Knebel, F., Nienaber, C., Werner, D., Aron, W., Remppis, B., Hambrecht, R., Kisters, K., Werner, N., Hoffmann, S., Rossol, S., Geiss, E., Graf, K., Hamann, F., von Scheidt, W., Schwinger, R., Tebbe, U., Costard-Jaeckle, A., Lueders, S., Heitzer, T., Leutermann-Oei, M.-L., Braun-Dullaeus, R., Roehnisch, J.-U., Muth, G., Goette, A., Rotter, A., Ebelt, H., Olbrich, H.-G., Mitrovic, V., Hengstenberg, C., Schellong, S., Zamolyi, K., Vertes, A., Matoltsy, A., Palinkas, A., Herczeg, B., Apro, D., Lupkovics, G., Tomcsanyi, J., Toth, K., Mathur, A., Banker, D., Bharani, A., Arneja, J., Khan, A., Gadkari, M., Hiremath, J., Patki, N., Kumbla, M., Santosh, M. J., Ravikishore, A. G., Abhaichand, R., Maniyal, V., Nanjappa, M., Reddy, P. N., Chockalingam, K., Premchand, R., Mahajan, V., Lewis, B., Wexler, D., Shochat, M., Keren, A., Omary, M., Katz, A., Marmor, A., Lembo, G., Di Somma, S., Boccanelli, A., Barbiero, M., Pajes, G., De Servi, S., Greco, D. C., De Santis, F., Floresta, A., Visconti, L. O., Piovaccari, G., Cavallini, C., Di Biase, M., Masini, D. F., Vassanelli, C., Viecca, M., Cangemi, D. F., Pirelli, S., Borghi, C., Volpe, M., Branzi, A., Percoco, D. G., Severi, S., Santini, A., De Lorenzi, E., Metra, M., Zaca, V., Mortara, A., Tranquilino, F. P., Babilonia, N. A., Ferrolino, A. M., Manlutac, B., Dluzniewski, M., Dzielinska, Z., Nowalany-Kozie, E., Mazurek, W., Wierzchowiecki, J., Wysokinski, A., Szachniewicz, J., Romanowski, W., Krauze-Wielicka, M., Jankowski, P., Berkowski, P., Szelemej, R., Kleinrok, A., Kornacewicz-Jac, Z., Vintila, M., Vladoianu, M., Militaru, C., Dan, G., Dorobantu, M., Dragulescu, S., Kostenko, V., Vishnevsky, A., Goloschekin, B., Tyrenko, V., Gordienko, A., Kislyak, O., Martsevich, S., Kuchmin, A., Karpov, Y., Fomin, I., Shvarts, Y., Orlikova, O., Ershova, O., Berkovich, O., Sitnikova, M., Pakhomova, I., Boldueva, S., Tyurina, T., Simanenkov, V., Boyarkin, M., Novikova, N., Tereschenko, S., Zadionchenko, V., Shogenov, Z., Gordeev, I., Moiseev, V., Wong, R., Ong, H. Y., Le Tan, J., Goncalvesova, E., Kovar, F., Skalina, I., Kasperova, V., Hojerova, S., Szentivanyi, M., Stancak, B., Babcak, M., Kycina, P., Poliacik, P., Toth, P., Sirotiakova, J., de Sa, E. L., Bueno, M. G., Selles, M. M., Cabrera, J. A., Freire, R. B., Gonzalez Juanatey, J. R., Comin, J., Soriano, F., Lopez, A., Vicho, R., Lama, M. G., Schaufelberger, M., Brunotte, R., Ullman, B., Hagerman, I., Cizinsky, S., Cherng, W.-J., Yu, W.-C., Kuo, C.-T., Chang, K.-C., Lai, W.-T., Kuo, J.-Y., Ural, D., Badak, O., Akin, M., Yigit, Z., Yokusoglu, M., Yilmaz, M., Abaci, A., Ebinc, H., Perlman, R., Parish, D., Bergin, J., Burnham, K., Brown, C., Lundbye, J., Williams, C., Eisen, H., Juneman, E., Joseph, S., Peberdy, M. A., Peura, J., Gupta, V., Habet, K., French, W., Mody, F., Graham, S., Hazelrigg, M., Chung, E., Dunlap, S., Nikolaidis, L., Najjar, S., Katz, R., Murali, S., Izzo, J. L., Callister, T., Phillips, R., Lippolis, N., Winterton, J., Meymandi, S., Heilman, K., Oren, R., Zolty, R., Brottman, M., Gunawardena, D. R., Adams, K., Barnard, D., Klapholz, M., & Fulmer, J.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-02
- Volume
- 34
- Issue
- 40
- Pages
- 3117-3127
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2160191188
- Cited by
- 56
- References
- 8
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. https://app.cochat.ai/papers/10.1093/eurheartj/eht342
- The paper
- Maggioni, A. P., Greene, S. J., Fonarow, G. C., Bohm, M., Zannad, F., Solomon, S. D., Lewis, E. F., Baschiera, F., Hua, T. A., Gimpelewicz, C. R., Lesogor, A., Gheorghiade, M., for the ASTRONAUT Investigators and Coordinators, Ramos, S., Luna, A., Miriuka, S., Diez, M., Perna, E., Luquez, H., . . . Fulmer, J. (2013). Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal. https://doi.org/10.1093/eurheartj/eht342
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.